Synapse - Omar Abdel-Wahab

Results (7)

Vemurafenib and obinutuzumab as frontline therapy for hairy cell leukemia

Journal Article

Park, J. H.; Devlin, S.; Durham, B. H.; Winer, E. S.; Huntington, S.; von Keudell, G.; Vemuri, S.; Shukla, M.; Falco, V.; Cuello, B.; more...
NEJM Evidence (2023)

Fulltext@MSK | Save

Long‐term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL

Meeting Abstract

Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A. M.; Noy, A.; more...
Hematological Oncology (2023)

Fulltext@MSK | Save

Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence

Meeting Abstract

Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
Blood (2021)

Fulltext@MSK | Save

Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen)

Meeting Abstract

Kumar, A.; Soumerai, J. D.; Abramson, J. S.; Batlevi, C. L.; Chadha, P.; Dogan, A.; Falchi, L.; Flaherty, K.; Friedman, C.; Grieve, C.; more...
Blood (2021)

Fulltext@MSK | Save

Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial